Anticancer Drugs Oncology Panobinostat Pharmacology Physiotherapy

Panobinostat and Myelosuppression

In this article we will discuss Panobinostat and Myelosuppression

In this article, we will discuss Panobinostat and Myelosuppression. So, let’s get started.

Panobinostat and Myelosuppression

Interrupt or reduce the dose of Panobinostat in patients who have thrombocytopenia, neutropenia or anemia according to instructions in Table 3. For patients with severe thrombocytopenia, consider platelet transfusions. Discontinue Panobinostat treatment if thrombocytopenia does not improve despite the recommended treatment modifications or if repeated platelet transfusions are required. In the event of Grade 3 or 4 neutropenia, consider dose reduction and/or the use of growth factors (e.g., G-CSF). Discontinue Panobinostat if neutropenia does not improve despite dose modifications, colony-stimulating factors, or in case of severe infection.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.